Pages

Thursday, March 5, 2015

中裕TMB-355 phase III 美FDA修正收案300人為30人 !!!

中裕抗愛滋藥 須補做小規模臨床 2015-03-04 經濟日報 記者黃文奇╱即時報導 中裕新藥(4147)今日宣布,有關旗下抗愛滋病新藥TMB-355Ibalizumab)靜脈注射臨床三期事宜,美國食品藥物管理局(FDA)明確指示,該產品藥證申請前僅需補作一個小型三期臨床試驗。中裕說,經過兩個月與美國FDA數次會議討論之結論,茲考慮孤兒藥資格、突破性治療資格以及TMB-355(Ibalizumab)靜脈注射現行各項發展狀況(包括CMO生產製造),美國FDA決議在該產品申請藥證申請前須補作一個小型三期臨床試驗,招募受試人數不低於30人即可。在意義上,中裕認為,這將大幅降低原先2011年美國FDA之三期臨床試驗300人要求,且臨床試驗計畫提出申請後即可進行不需等待審核,未來並可滾動式方式提出藥證申請及審核,以加速相關作業流程。

中裕愛滋新藥 藥證進度加速 20150305 04:10 記者杜蕙蓉/台北報導 中裕(4147)愛滋新藥TMB-355Ibalizumab)靜脈注射藥證進度大步。在取得美國FDA突破性治療資格(Breakthrough Therapy)後,FDA已同意僅需補作一個不低於30人的小型三期臨床試驗,是原本設計300個人數的十分之一,而且可採滾動式方式提出藥證申請及審核。

以時程推算,法人預估,TMB-355有機會力拚明年上半年取得藥證。 中裕表示,TMB-355靜脈注射臨床三期事宜,經過兩個月與美國食品藥物管理局(FDA)數次會議討論的結論,因考慮孤兒藥資格、突破性治療資格以及TMB-355行各項發展狀況(包括CMO生產製造),FDA明確指示TMB-355在申請藥證申請前僅需補做一個小型三期臨床試驗,招募受試人數不低於30人,大幅降低2011FDA的三期臨床試驗300人要求。該臨床試驗計畫提出申請後即可進行不需等待審核,未來並可滾動式方式提出藥證申請及審核,以加速相關作業流程。有機會以台灣品牌拿下美國FDA第一張新藥藥證的中裕,去年稅後損失28,173萬元,每股淨損1.32元。中裕執行長張念原去年股東會時表示,美國愛滋病患接受治療的約80萬人,屬於後期族群約510萬人,可用藥物56種,初估若23萬人適合用TMB-355靜脈注射型,其中1/3患者使用TMB-355,以過去後期愛滋病用藥一年平均約花費2萬美元計算,TMB-355未來市場價值至少2億美元。TMB-355還發展肌肉及皮下注射劑型,並分別在台灣進行一/二期人體臨床試驗中。

IV TMB-355: A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)Enrollment: 113/Study Start Date: August 2008/Study Completion Date:   April 2011

SC TMB-355: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers. Enrollment: 25/ Study Start Date: February 2011/ Study Completion Date: September 2012

安成生物 跨入big data 掘金世代! (Medidata Rave/ Medidata Coder)

安成生物科技選擇 Medidata 技術 提升代謝性疾病創新臨床研究的效率和速度 中央社 (2015-02-17 09:00)擁有獨步全球的專利技術,擁有最先進之實驗室,是生物科技生活化之領航者 (中央社訊息服務20150217 09:00:29)全球領先的生命科學臨床研究領域雲解決方案供應商Medidata(那斯達克代號:MDSO)今日宣佈安成生物科技有限公司(TWi Biotechnology, Inc) 決定採用該公司領先業界的技術平台。作為臺灣一家領先的生物製藥公司,安成生物科技選擇 Medidata Clinical Cloud以提升公司新開展的代謝性疾病臨床研究的速度、品質和效率。安成生物科技總經理陳志光(Calvin Chen)博士表示:「Medidata平台已經在全球範圍內被廣泛採用,它不僅有助於安成生物科技提升效率,同時可以確保研究機構和臨床研究協調人員熟悉並使用此項技術。我們很高興能夠與 Medidata攜手合作,共同應對目前未獲滿足的醫療需求,並持續為全球患者提供創新且高品質的治療方案。」安成生物科技致力於為新陳代謝、罕見疾病和皮膚病學領域目前未獲滿足的醫療需求研發創新型療法。為了優化代謝性疾病第II階段的研究,安成生物科技採用 Medidata 雲技術進行電子資料的採集和管理 (Medidata Rave) 以及醫學編碼 (Medidata Coder)除了可以通過實時數據輸入提升效率,Medidata 技術解決方案還可以為安成生物科技提供更有效的臨床試驗監督,從而能夠更早和掌握更多資訊以做出更明智的決策。Medidata 亞太地區董事總經理山本武(Takeru Yamamoto)先生表示:「亞太新興市場在生命科學行業未來的增長潛力巨大。對於安成生物科技選擇 Medidata 的技術為其重要研究提供支持,我們感到很振奮,這同時也讓我們有機會為臺灣乃至亞洲市場的藥物研發領域貢獻我們的力量,從而有可能推進目前未獲滿足的重要醫療需求領域的創新療法。」

關於安成生物科技 安成生物科技股份有限公司(TWi Biotechnology, Inc.)為安成國際藥業股份有限公司(TWi Pharmaceuticals, Inc.)的獨資子公司,是一家領先的臨床階段生物製藥公司,總部位於臺灣臺北市,專門從事用於無適當醫藥可滿足現有需求(unmet medical needs)之創新藥物的開發,尤其是先天免疫力有關疾病藥物的發展。安成生物科技的產品開發系列包括三個候選藥物用於治療二型糖尿病,關節炎和免疫性皮膚疾病。

關於 Medidata Medidata是全球領先的生命科學臨床研究領域雲解決方案供應商,通過其先進的應用程式和電子資料分析改善臨床開發。Medidata Clinical Cloud 為極具發展前景的藥物治療臨床試驗提升效率和品質,使研究的設計、規劃以及執行,管理和報告均得到提升。我們致力於協助全球客戶推進市場競爭與科學研究的目標。我們的客戶包括全球前25名的製藥公司中90%以上的企業,創新型生物技術、診斷和設備公司,以及領先的學術醫學中心和合同研究組織(CRO)。訊息來源:Medidata

Medidata 大數據 開發幼童關節炎Childhood Arthritis治療策略!!

Medidata's Cloud and Mobile Technology Selected to Drive Collaborative, 10-Year Research in Pediatric Rheumatology  February 23, 2015 08:30 AM Eastern Standard Time  NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it has been selected to support the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, a 10-year project to collect comprehensive data on pediatric rheumatic diseases and their treatments. "This is a critical next step in understanding how to best apply available therapies and improve the systems for studying the safety and efficacy of treatment options for childhood-onset arthritis."  "While we've made huge progress in the last decade, 300,000 children and families in the US alone are affected by rheumatic diseases," said Laura Schanberg, MD, professor of pediatrics at Duke University and CARRA president and the principal investigator for the CARRA Registry, an observational study of children and adolescents with major rheumatic diseases. By powering data capture for the scalable informatics infrastructure of the CARRA Registry, the Medidata Clinical Cloud® will help CARRA develop a resource for patients, physicians and researchers seeking to learn more about pediatric rheumatic diseases, and, ultimately, drive better diagnostic and treatment approaches.  In support of its long-term research efforts, the registry is leveraging Medidata's cloud-based technology for electronic data capture and management (Medidata Rave®) and mobile solution for patient-direct data capture (Medidata Patient Cloud®). A mobile app unified with Medidata's platform, Patient Cloud brings new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials and registries. The mobile app provides electronic patient questionnaires and diaries in a model that simplifies the process for both patients and researchers.  "Using Medidata's platform in combination with the open-source, i2b2 federated clinical research data warehouse platform already in use for the CARRA Registry, this post-marketing surveillance network will collect at least 10 years of comprehensive information, including detailed safety and treatment data, on pediatric rheumatic disorders in the US and Canada," said Marc Natter, MD, the CARRA Registry's director of informatics development and instructor in the Boston Children's Hospital Informatics Program. "This is a critical next step in understanding how to best apply available therapies and improve the systems for studying the safety and efficacy of treatment options for childhood-onset arthritis." Dedicated to advancing the health and quality of life of children living with rheumatic disease and arthritis, CARRA was formed by pediatric rheumatologists seeking to answer critical clinical research questions. "Juvenile idiopathic arthritis and other pediatric inflammatory disorders result in persistent joint pain, swelling and stiffness of joints, decreased activity, and potentially growth and eye problems," Schanberg added. "Children lose days from school, parents lose days from work and quality of life suffers greatly. We believe that simplifying data capture and patient participation processes will catapult the field of pediatric rheumatology research to the level of performance necessary to realize dramatic improvements in outcomes and quality of life for all children with rheumatic disease."  Glen de Vries, Medidata's president, said: "We're excited to be partnering with CARRA on this observational study and proud that our technology platform is helping to further the alliance's important mission to prevent, treat and cure arthritis and other rheumatic diseases in children and adolescents. All of us at Medidata share CARRA's commitment to fostering, facilitating and conducting high-quality research that advances the development of new, enhanced diagnostic and treatment approaches."

About CARRA  CARRA is a North American non-profit research organization of more than 400 pediatric rheumatologists, researchers and research coordinators at more than 100 sites (95% of all pediatric rheumatologists/sites in North America) who are working together to find treatments for juvenile idiopathic arthritis and other pediatric rheumatic diseases in children.  The CARRA Registry is a cornerstone of CARRA and provides disease and treatment data on children with a variety of rheumatic diseases. CARRA aims to make it possible for all affected children in North America to have the opportunity to participate in meaningful and high quality clinical and translational research. CARRA researchers have been awarded over $40 million in research funding over the last 10 years. In addition to Dr. Schanberg, the CARRA Executive team includes Yukiko Kimura, MD, Hackensack University Medical Center, Norman Ilowite, MD, Montefiore Medical Center, and Robert Fuhlbrigge, MD, PhD, Boston Children's Hospital. 

About Medidata Solutions  Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Juvenile rheumatoid arthritis (JRA)  Etiology and Pathophysiology  The etiology and pathogenesis of JIA are not completely understood. Genetic susceptibility plays a major role, but there is significant overlap between loci associated with JIA and those associated with other autoimmune diseases. JIA is a genetically complex disorder in which multiple genes are important for disease onset and manifestations. The IL2RA/CD25 gene has been implicated as a JIA susceptibility locus, as has the VTCN1 gene.[8] Associations have been found between specific HLA alleles and clinical subtypes of JIA (eg, HLA-A(*)02:06 with susceptibility to JIA accompanied by uveitis, and HLA-DRB1(*)04:05 with polyarticular JIA, in a Japanese cohort). Humoral and cell-mediated immunity are involved in the pathogenesis of JIA. T lymphocytes have a central role, releasing proinflammatory cytokines (eg, tumor necrosis factor–alpha [TNF-α], interleukin [IL]-6, IL-1) and favoring a type-1 helper T-lymphocyte response. A disordered interaction between type 1 and type 2 T-helper cells has been postulated. Studies of T-cell receptor expression confirm recruitment of T-lymphocytes specific for synovial nonself antigens. Evidence for abnormalities in the humoral immune system include the increased presence of autoantibodies (especially antinuclear antibodies), increased serum immunoglobulins, the presence of circulating immune complexes, and complement activation. Chronic inflammation of synovium is characterized by B-lymphocyte infiltration and expansion. Macrophages and T-cell invasion are associated with the release of cytokines, which evoke synoviocyte proliferation. A study by Scola et al found synovium to contain messenger ribonucleic acid (mRNA) for vascular endothelial growth factor and angiopoietin 1, as well as for their receptors, suggesting that induction of angiogenesis by products of lymphocytic infiltration may be involved in persistence of disease. Some pediatric rheumatologists view systemic-onset JIA as an autoinflammatory disorder, such as familial Mediterranean fever (FMF) or cryopyrin-associated periodic fever syndromes, rather than a subtype of JIA. This theory is supported by work demonstrating similar expression patterns of a phagocytic protein (S100A12) in systemic-onset JIA and FMF, as well as the same marked responsiveness to IL-1 receptor antagonists. FMF is associated with mutations in the MEFV gene; these mutations are associated with activation of the IL-1b pathway, resulting in inflammation. A study by Ayaz et al found an increased frequency of MEFV mutations in Turkish children who were diagnosed with systemic JIA[12] ; this study has not been replicated in other populations.

Source: Medscape

安成藥 購現增1.1億 (安成生技25元/股)

安成藥業:本公司董事會通過變更認購子公司安成生物科技股份有限公司現金增資發行新股案鉅亨網/鉅亨網新聞中心-20150129 下午19:08 第二條 第201. 原公告日期:103/03/112. 簡述原公告申報內容:本公司103/03/11董事會通過將以不逾新台幣100,000,000元,認購子公司安成生物科技股份有限公司現金增資發行新股案,以每股新台幣25元價格認購,預計認購4,000,000股為上限。3. 變動緣由及主要內容:因應安成生物科技股份有限公司變更其增資發行計畫。故本公司將依照安成生物科技股份有限公司所變更之現金增資發行計畫,將以不逾新台幣117,640,000,認購子公司安成生物科技股份有限公司現金增資發行新股案,以每股新台幣10元價格認購。4. 變動後對公司財務業務之影響:無5. 其他應敘明事項:無

中裕TMB-355(ibalizumab)未來支付Genentech授權金(FDA核准上市時)

FDA點頭!中裕愛滋新藥獲突破性治療資格 2015/3/2鉅亨網提供 興櫃新藥廠中裕新藥(4147)旗下愛滋新藥大步走!宣布獲美國食品藥物管理局(FDA)通知,審核通過研發中愛滋病新藥TMB-355(ibalizumab)靜脈注射型應用於多重抗藥性病人獲得突破性治療資格(Breakthrough Therapy) 中裕表示,獲此資格後,美國FDA將指定專人協助與溝通及指引藥物上市發展各項開發計畫。 中裕指出,公司現階段愛滋病新藥TMB-355(ibalizumab)靜脈注射型先前已獲得美國FDA核准快速審查以及孤兒藥兩項資格,其中未來靜脈注射型,將進行三期臨床試驗,必與FDA協商確認及新藥查驗登記審查,另外肌肉及皮下注射型,則是臨床一、二期試驗、三期臨床試驗、新藥查驗登記審查。中裕進一步指出,肌肉及皮下注射劑型三期臨床試驗規劃及範圍,需依據一、二期臨床試驗結果而定,若一切順利完成,三期試驗完成時間約在2017-2018年,靜脈注射劑型發展時程需視與FDA協商範圍決定,執行及完成三期臨床試驗並不需要給付給原授權對象Genentech相關哩程授權金,美國FDA核准上市時才需給付Genentech相關哩程授權金

孤兒藥真假利基?! (快速審查/自由定價/獨占市場)

孤兒藥市場 台廠有利基 2015-03-02 經濟日報 記者黃文奇/台北報導 孤兒藥有商機,台廠得利。美國食品藥物管理局(FDA)所核定的孤兒藥資格,台廠目前包括國鼎、藥華藥、中裕、心悅、台微體、智擎等旗下藥物,均符合該資格,兩年內可望有產品問世,搶攻罕病用藥市場。孤兒藥(Orphan drug)即罕見疾病用藥,是歐美等先進國家藥物管理單位所訂定的藥品特殊資格,是為了鼓勵藥廠開發小眾且困難的疾病藥物,如美國FDA規定,每年發病病患人數不足20萬(各國規定不盡相同)且未有主流用藥的困難疾病,即可申請孤兒藥資格認定。若產品獲取孤兒藥資格,大多可享有快速通關的審查資格,未來上市後也可能享有自由定價、獨占市場等優惠條件。台灣於2000年公布實行罕藥法,為繼美國、日本、澳洲與歐盟之後,第五個以公權力保障罕見疾病醫療的國家,而台灣對罕見疾病的定義為患病數在萬分之一以下。其中,國鼎生技旗下抗胰臟癌適應症產品Antroquinonol,近期獲得美國FDA的孤兒藥資格,該產品是國鼎生技於2005年開發出來的化學新藥,主要應用在抗非小細胞肺癌適應症方面,目前已經進入臨床二期,而抗胰臟癌適應症獲得孤兒藥認證後,將縮短該適應症臨床試驗的時程。在此之前,另有藥華藥、台微體、中裕、心悅等公司產品,除了均先後獲得美國FDA孤兒藥認證,產品也均進入臨床試驗,成果豐碩。其中,台微體肝癌新藥LIPOTECAN,目前在兩岸均已進入臨床二期試驗。特別的是,因孤兒藥資格而受惠的廠家莫過於中裕、藥華藥,中裕的抗愛滋病用藥TMB-355靜脈注射產品,已經早完成臨床二期試驗,可能因此一資格而獲得快速通關。該公司執行長張念原及其團隊將於3月上旬與美國FDA協商,是否需繼續進行第三期臨床試驗或補做小規模臨床,屆時即可分曉。除了孤兒藥資格之外,心悅生醫與中裕近期也都獲得美國FDA的突破性療法(breakthrough therapy)資格,據了解,獲得「突破性療法」資格的產品必須符合「重大疾病、顯著療效」等兩大條件,擁有該資格的產品在全球僅約60個,新藥則更少約15個,未來美國FDA將主動介入輔導產品儘速上市。

重庆健康優選 保健品電商試點平台 (黃伊嘉&第一堂連鎖藥房)

互貴引路 台糖保健品攻陸 20150224 04:10 記者杜蕙蓉/台北報導 互貴興業與重慶健康優選公司戰略合作再添新案源!據了解,台糖9項健字號的保健品將透過該平台進軍大陸。健康優選合夥人黃伊嘉表示,大陸保健品市場超過4千億人民幣,但對保健食品的認識品項卻不多,還停留在魚油、鈣片和Q10等產品,因此,台灣廠商有很大的利基。健康優選是中國政府特批的試點平台,可以發展跨境(海外)電商。爾後台灣保健產品,均可透過此電子商務通路,不需經由CFDA及海關等證照申請,即可合法在大陸銷售。目前已有泰合、金穎、雙美、台糖等公司透過互貴引薦與健康優選合作,以電商平台方式銷售。黃伊嘉表示,中國的電商銷售是全球發展最好、也最快速的產業,健康優選雖然是20148月才創立,但目前已有上千個境外品項透過該平台進軍大陸,這次將引進台糖的保健品包括有乳酸菌、寡糖等健字號產品。為了加速境外產品在中國打開知名度,黃伊嘉說,健康優選近期將引進優秀的執行長,目前已規劃至少6種行銷策略。台灣出生的黃伊嘉,是在英國讀書時認識重慶第一堂連鎖藥房的大股東而合資創立健康優選,也順利取得中國政府特批的試點平台。黃伊嘉表示,中國保健品市場商機龐大,但還是處女地,民眾普遍對保健品的認識不夠多,因此,如果有靈活的行銷手法和教育,保健品大餅,台灣廠商吃得到。互貴興業執行長郭加泳表示,健康優選除了有優勢電商平台外,還有策略聯盟的第一堂連鎖藥房。第一堂藥房為實體通路,在中國加盟點超過 5,000家,2015年看上1萬家連鎖,如果台灣保健食品在健康優選平台銷量不錯,等大批量海關正式進口,就可以透過第一堂藥房平台 ,展開全中國的通路鋪貨。另外,宣捷集團總經理宣昶有透露,為了加速前進大陸,目前互貴也和宣捷聯盟,將同步在各省設點,發揮乘數效益。

健康优选介绍 一、建立背景 重庆健康优选电子商务有限公司是为响应中国跨境电子商务试点,20148月由上海哲舟实业有限公司、西藏承亿医药科技有限公司及重庆居家易医药有限公司共同发起成立,其中以上海哲舟实业为控股公司,注册于重庆。旗下健康优选网站是专业运营海外母婴类产品的第三方垂直海外购物网站,为中国消费者、合作商、实体店提供订购、经销、代理全球优质母婴产品专业一体化的服务。

二、网站介绍"健康优选"网站是重庆健康优选电子商务有限公司旗下以母婴产品为主要经营项目的海外官方直邮购物网站。"健康优选"创始团队在充分总结国内外母婴产品销售的经验后,经多年策划于201410月正式上线运营。"健康优选"立足医药科技企业,专业采购团队采用高于行业的标准,精心甄选优质进口母婴产品,通过厂家直接发货的直邮模式,保证产品的质量及价格的优势。20149月正式与重庆海关建立跨境贸易电子商务对接业务,享有快速通关、清关等便利。不仅如此,"健康优选"的消费者还可以通过"重庆跨境贸易电子商务服务网"对购买的产品进行详情查询、个人消费额度查询以及税单查询等,还能够通过产品包裹单条形码来验证商品的真伪。

三、网站优势

1.专业团队 医药科技企业背景,具有一定医疗知识的专业团队。

2. 一站式服务 通过与海外供应商、国内物流以及支付公司的合作,构成了消费者从网站购物、商品配送以及售后服务的一站式服务支撑体系。3. 海外直邮 海外供应商直接发货,不经过网站中转,消费者可享快速、低价的优质商品及服务。4. 正品保证 重庆海关后台商品详情查询、防伪查询。5. 政府支持 作为重庆市政府大力扶持的电子商务企业,享有特殊政策以及海关的绿色通道。6. 通关优势 与重庆海关建立了跨境贸易电子商务对接业务,享受快速清关等便利。7. 售后保障 采用海外直邮模式,避免了商品中转次数多,耗费时间长及产品质量等问题,同时,可在重庆海关后台,对相关产品的真伪进行查询。

四、发展前景 在电子商务蓬勃发展的今天,海外购物已经不再新鲜,身处移动互联时代的我们,不仅想为消费者提供更优质商品,已筹划并实现了利用O2O模式为消费者提供更加优质的服务,"健康优选"与各地"第一堂"药店已达成战略合作协议,将充分利用各地实体"第一堂"药店,让消费能享受线上购物就近提货的便利体验。

新藥找專家/ 宣明智: 生技眉角太多

生技眉角多 宣明智:靠連結 創造效益 20150224 04:10 記者杜蕙蓉/專訪 從電子大亨到生技A咖,宣捷集團董事長宣明智在短短幾年內已儼然成為兩岸生技大使,不僅曾率領國內生技產業界拜訪國務院、科技部、食品藥品監督管理總局等重要部會,兩岸重要的生技交流會,他也常是座上賓。多年前和兒子宣昶有一起創立宣捷集團,從幹細胞到兩岸搭橋,宣明智講起幹細胞頭頭是道,已經是專家級了,而不管是莞榕計劃或是互貴興業搭的平台,他至少已帶進超過10家企業進軍大陸。宣明智表示,生技眉角太多,必須要有好的連結才能創造最大效益,以下是他的看法紀要:問:經歷去年基亞事件的震撼教育和生技股價修正已長達半年多,你對生技產業的看法有修正嗎?答:股價我沒有特別留意,但生技產業我還是很看好。我認為生技產業領域太廣又很深,每一樣都有很多「眉眉角角」,不過,好東西一定可以依附存在,但要靠有效連結,才會產生效益。問:你投資生技產業的領域很廣泛,要如何創造效益?答:除了新藥難度很高,必須靠專家外,絕大部分投資,我是從終端市場回推!從通路、商品往前到轉譯、技術,再向前看原創的想法。例如,宣捷幹細胞和宣捷生技就是一條龍式的整合,從產婦篩檢平台、嬰兒細胞的儲存,再發展至再生醫學,甚至是新藥開發。互貴興業的兩岸搭橋平台,引薦國內成熟的保健品、美容保養品、醫材等品項,透過中國試點平台,無須先報關,即能在大陸銷售。 問:你領軍的莞榕計劃和互貴興業成效如何?答:整體來看還不錯!與東莞政府合作「莞榕計畫」,目前在東莞松山湖生技園區設立公司,有晉弘科技、訊映光電、普生、雙美、泰合,還有農業生技的百泰和檢驗試劑為主的亞諾法也將進軍。互貴則除了泰合、雙美、台糖等,景岳也可望加入健康優選的電商平台。問:目前投資的生技公司有規劃IPO嗎?那家進度最快?答:我們的生技投資都還處於布局階段,宣捷幹細胞已經有營業額,但對上市掛牌計劃,我是抱著「水到渠成」看法,一切照法規走,等時間點對了,自然就會上市櫃。